Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies how well CBX-12 works in treating patients with solid tumors that
have spread from where they first started (primary site) to started to nearby tissue, lymph
nodes, or distant parts of the body (advanced) or other places in the body (metastatic).
CBX-12 works by binding to a protein called TOP1 that is present inside the cells. This
allows CBX-12 to kill the cancer cells by damaging their DNA, resulting in cancer cell death.
This trial is being done to find out if this approach is better or worse than the usual
approach for advanced cancers.